Axsome Therapeutics (AXSM) News Today → What is Nvidia doing on June 10? June 10th is pivotal for Nvidia’s “Silent Partners” (From Weiss Ratings) (Ad) Free AXSM Stock Alerts $73.43 -0.78 (-1.05%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 31 at 6:06 AM | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Mark Coleman Sells 5,249 SharesMay 30 at 8:12 AM | americanbankingnews.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) COO Mark L. Jacobson Sells 7,910 SharesMay 30 at 7:55 AM | insidertrades.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells $394,777.29 in StockMay 29, 2024 | marketbeat.comInsider Selling: Axsome Therapeutics, Inc. (NASDAQ:AXSM) Director Sells 5,249 Shares of StockAxsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) Director Mark Coleman sold 5,249 shares of the stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $75.21, for a total transaction of $394,777.29. Following the completion of the sale, the director now owns 19,848 shares in the company, valued at $1,492,768.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.May 29, 2024 | globenewswire.comAxsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024May 28, 2024 | finance.yahoo.comAxsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) MeetingMay 25, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Shares Sold by Victory Capital Management Inc.Victory Capital Management Inc. lessened its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 72.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 5,208 shares of the company's stock after selling 13,726May 23, 2024 | americanbankingnews.comInvestors Buy Large Volume of Call Options on Axsome Therapeutics (NASDAQ:AXSM)May 22, 2024 | marketbeat.comStock Traders Buy High Volume of Call Options on Axsome Therapeutics (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) was the recipient of unusually large options trading on Wednesday. Stock investors bought 5,695 call options on the company. This is an increase of 483% compared to the typical volume of 977 call options.May 20, 2024 | markets.businessinsider.comHold Rating on Axsome Therapeutics Amidst Regulatory Strategy and Commercialization ProspectsMay 20, 2024 | marketbeat.comNational Bank of Canada FI Has $46,000 Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)National Bank of Canada FI cut its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 99.0% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 600 shares of the company's stock afterMay 19, 2024 | marketbeat.comSwiss National Bank Has $4.82 Million Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Swiss National Bank decreased its position in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 15.6% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 60,500 shares of the company's stock after selling 11,May 18, 2024 | fool.com3 Monster Stocks in the Making You Can Buy Right NowMay 17, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (AXSM)May 15, 2024 | marketbeat.comNicholas Investment Partners LP Sells 312,335 Shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM)Nicholas Investment Partners LP lessened its stake in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 79.1% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 82,645 shares of the company's stock after sMay 13, 2024 | finance.yahoo.com15 Most Depressed States in the USMay 11, 2024 | investorplace.comThe 3 Most Undervalued Biotech Stocks to Buy in May 2024May 11, 2024 | fool.comPrediction: These 2 Growth Stocks Could Triple By 2030May 11, 2024 | marketbeat.com21,086 Shares in Axsome Therapeutics, Inc. (NASDAQ:AXSM) Acquired by Truist Financial CorpTruist Financial Corp purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 21,086 shares of the company's stock, valued at approximateMay 10, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q2 2024 Earnings of ($1.31) Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at HC Wainwright lowered their Q2 2024 earnings estimates for Axsome Therapeutics in a research note issued on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per shaMay 10, 2024 | seekingalpha.comWhy Axsome Therapeutics Is A Promising Stock Pick In CNS TreatmentsMay 9, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) First-Quarter Results: Here's What Analysts Are Forecasting For This YearMay 9, 2024 | marketbeat.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) to Post Q3 2025 Earnings of $0.47 Per Share, HC Wainwright ForecastsAxsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Analysts at HC Wainwright dropped their Q3 2025 EPS estimates for shares of Axsome Therapeutics in a report released on Tuesday, May 7th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings per share of $0.47 fMay 8, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Price Target Lowered to $106.00 at MizuhoMizuho lowered their price target on shares of Axsome Therapeutics from $109.00 to $106.00 and set a "buy" rating on the stock in a report on Wednesday.May 8, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Axsome Therapeutics Amidst Strong Q1 Earnings and Promising Clinical TrialsMay 8, 2024 | marketbeat.comFY2026 EPS Estimates for Axsome Therapeutics, Inc. Reduced by Analyst (NASDAQ:AXSM)Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) - Investment analysts at Leerink Partnrs reduced their FY2026 earnings per share (EPS) estimates for Axsome Therapeutics in a report released on Monday, May 6th. Leerink Partnrs analyst M. Goodman now anticipates that the company will earn $1.May 8, 2024 | globenewswire.comAxsome Therapeutics to Present at Upcoming Investor ConferencesMay 7, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) PT Lowered to $125.00Citigroup cut their target price on Axsome Therapeutics from $127.00 to $125.00 and set a "buy" rating on the stock in a research note on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed on Axsome Therapeutics Amid Strong Sales and Strategic PositioningMay 7, 2024 | finance.yahoo.comAxsome Therapeutics, Inc. (NASDAQ:AXSM) Q1 2024 Earnings Call TranscriptMay 7, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Reiterated by HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $190.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday.May 7, 2024 | marketbeat.comRobert W. Baird Boosts Axsome Therapeutics (NASDAQ:AXSM) Price Target to $112.00Robert W. Baird boosted their price target on Axsome Therapeutics from $108.00 to $112.00 and gave the stock an "outperform" rating in a research report on Tuesday.May 7, 2024 | markets.businessinsider.comBuy Rating Affirmed for Axsome Therapeutics on Strong Auvelity Sales and Market Expansion PotentialMay 7, 2024 | finance.yahoo.comAxsome Therapeutics Inc (AXSM) (Q1 2024) Earnings Call Transcript Highlights: Soaring Revenues ...May 7, 2024 | finance.yahoo.comQ1 2024 Axsome Therapeutics Inc Earnings CallMay 6, 2024 | fool.comAxsome Therapeutics (AXSM) Q1 2024 Earnings Call TranscriptMay 6, 2024 | investorplace.comAXSM Stock Earnings: Axsome Therapeutics Beats EPS, Beats Revenue for Q1 2024May 6, 2024 | washingtonpost.comAxsome: Q1 Earnings SnapshotMay 6, 2024 | msn.comAxsome Therapeutics GAAP EPS of -$1.44 misses by $0.21, revenue of $75M beats by $2.15MMay 6, 2024 | globenewswire.comAxsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdateMay 2, 2024 | stocknews.comInvestors Beware of These 3 Pharma StocksMay 2, 2024 | marketbeat.comCannell & Co. Lowers Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)Cannell & Co. lowered its position in Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 20.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 82,845 shares of the company's stock after selling 21,345 shares during the period. CannellMay 1, 2024 | globenewswire.comAxsome Therapeutics Recognizes May as Mental Health Awareness MonthApril 30, 2024 | investorplace.com3 Biotech Stocks with Blockbuster Drug Pipelines: April EditionApril 29, 2024 | finance.yahoo.comGinkgo Bioworks Announces Nomination of Myrtle Potter and Ross Fubini to Board of DirectorsApril 29, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71Axsome Therapeutics (NASDAQ:AXSM) Shares Gap Up to $71.71April 29, 2024 | markets.businessinsider.comBuy Rating on Axsome Therapeutics Amidst Strong Auvelity Performance and Positive Revenue ProspectsApril 29, 2024 | msn.comAxsome Therapeutics stock rises on upgrade to Overweight at Morgan StanleyApril 29, 2024 | markets.businessinsider.comPeeling Back The Layers: Exploring Axsome Therapeutics Through Analyst InsightsApril 29, 2024 | marketbeat.comAxsome Therapeutics (NASDAQ:AXSM) Rating Increased to Overweight at Morgan StanleyMorgan Stanley upgraded shares of Axsome Therapeutics from an "equal weight" rating to an "overweight" rating and upped their target price for the company from $90.00 to $115.00 in a report on Monday. Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address The Worst is Yet to Come… (Ad)Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly. Click here to stream this controversial exposé now. AXSM Media Mentions By Week AXSM Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AXSM News Sentiment▼0.250.76▲Average Medical News Sentiment AXSM News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AXSM Articles This Week▼96▲AXSM Articles Average Week Get Axsome Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AXSM and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: INSM News HCM News BHVN News RARE News PRGO News ALKS News PBH News ARWR News IDYA News SMMT News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:AXSM) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Axsome Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
